Smith & Nephew SNATS (NYSE: SNN) and Cyberonics (NASDAQ:CYBX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitabiliy, dividends and earnings.

Valuation and Earnings

This table compares Smith & Nephew SNATS and Cyberonics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Smith & Nephew SNATS $4.67 billion 3.27 $1.29 billion N/A N/A
Cyberonics N/A N/A N/A N/A N/A

Smith & Nephew SNATS has higher revenue and earnings than Cyberonics.


This table compares Smith & Nephew SNATS and Cyberonics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Smith & Nephew SNATS N/A N/A N/A
Cyberonics 15.33% 17.49% 15.23%


Smith & Nephew SNATS pays an annual dividend of $0.61 per share and has a dividend yield of 1.7%. Cyberonics does not pay a dividend. Smith & Nephew SNATS has raised its dividend for 4 consecutive years.

Insider & Institutional Ownership

7.1% of Smith & Nephew SNATS shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Smith & Nephew SNATS and Cyberonics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew SNATS 0 6 2 0 2.25
Cyberonics 0 0 0 0 N/A


Smith & Nephew SNATS beats Cyberonics on 6 of the 9 factors compared between the two stocks.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.

Cyberonics Company Profile

Cyberonics, Inc. is a medical device company. The Company is engaged in the design, development, sale and marketing of medical devices for epilepsy, depression and heart failure. Its seminal product, the VNS Therapy System, is an implantable device that provides neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression (TRD). The Company’s VITARIA System is an implantable device that provides a form of neuromodulation therapy for the treatment of chronic heart failure (CHF). The VNS Therapy System and its VITARIA System include an implantable pulse generator to stimulate the vagus nerve; a lead that conducts current pulses from the pulse generator to the vagus nerve; a surgical instrument to assist with the implant procedure; equipment to enable the treating physician to set the pulse generator stimulation parameters for the patient; instruction manuals, and in the VNS Therapy System, magnets to suspend or induce stimulation manually.

Receive News & Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related companies with's FREE daily email newsletter.